Whitehawk Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Whitehawk Therapeutics Inc 's ROA in the second quarter of 2026?
Whitehawk Therapeutics Inc recorded a cumulative net loss of $-80 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -49.97%.

However, within the Healthcare sector 562 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 3797 to 4149.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	7.37 %	-45.63 %	114.49 %	94.89 %	78.88 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-80	-116	-21	-16	-10
Return On Assets (TTM)	-49.97 %	-74.03 %	-11.25 %	-9.58 %	-7.3 %
WHWK's Total Ranking	# 4149	# 3797	# 3272	# 3163	# 198
Total Assets (TTM) in million	194	127	151	167	181
Seq. Total Assets Change	52.47 %	-15.65 %	-9.69 %	-7.56 %	-22.79 %
Seq. Net Income Change	-	-	-	-	-

WHWK's 5 Years Annual ROA >> Back to WHWK Management Effectiveness >> Compare WHWK ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 244
Sector	# 563
Overall	# 3890

Return On Assets Statistics
High	Average	Low
22.47 %	-3498.54 %	-90038.63 %
(Mar 31 2025)		(Sep 30 2016)

Financial Statements
Whitehawk Therapeutics Inc 's Assets	$ 194 million	WHWK's Balance sheet
Whitehawk Therapeutics Inc 's Income	$ -17 million	Quarterly WHWK's Income Statement
WHWK's Income by Division		See WHWK's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	114.49 %	-46.88 %	-27.87 %	16.23 %	251.5 %
Total Assets in million	151	70	132	184	158
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-21	-64	-66	-61	-110
Annual Return On Assets	-13.66 %	-90.57 %	-49.68 %	-32.97 %	-69.72 %

WHWK's 5 Years Annual ROA >> Back to WHWK Management Effectiveness >> Compare WHWK ROA to its Competitors

More Return On Assets Ratios
WHWK's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
WHWK's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for WHWK's Competitors
Subscribers only: Roa for Whitehawk Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for WHWK's Customers

You may also want to know
WHWK's Roi	WHWK's Inventory Turnover Ratio	WHWK's Growth Rates	WHWK's Dividend Comparisons
	WHWK's Profitability Ratios	WHWK's Asset Turnover Ratio	WHWK's Dividend Growth
WHWK's Roe	WHWK's Valuation Ratios	WHWK's Financial Strength Ratios	WHWK's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:07:26+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.